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Abstract
Neuronal ceroid lipofuscinosis (NCL) is a progressive neurodegenerative disease characterized by brain and retinal atrophy
and the intracellular accumulation of autofluorescent lysosomal storage bodies resembling lipofuscin in neurons and other
cells. Tibetan terriers show a late-onset lethal form of NCL manifesting first visible signs at 5–7 years of age. Genome-wide
association analyses for 12 Tibetan-terrier-NCL-cases and 7 Tibetan-terrier controls using the 127K canine Affymetrix SNP
chip and mixed model analysis mapped NCL to dog chromosome (CFA) 2 at 83.71–84.72 Mb. Multipoint linkage and
association analyses in 376 Tibetan terriers confirmed this genomic region on CFA2. A mutation analysis for 14 positional
candidate genes in two NCL-cases and one control revealed a strongly associated single nucleotide polymorphism (SNP) in
the MAPK PM20/PM21 gene and a perfectly with NCL associated single base pair deletion (c.1620delG) within exon 16 of the
ATP13A2 gene. The c.1620delG mutation in ATP13A2 causes skipping of exon 16 presumably due to a broken exonic splicing
enhancer motif. As a result of this mutation, ATP13A2 lacks 69 amino acids. All known 24 NCL cases were homozygous for
this deletion and all obligate 35 NCL-carriers were heterozygous. In a sample of 144 dogs from eleven other breeds, the
c.1620delG mutation could not be found. Knowledge of the causative mutation for late-onset NCL in Tibetan terrier allows
genetic testing of these dogs to avoid matings of carrier animals. ATP13A2 mutations have been described in familial
Parkinson syndrome (PARK9). Tibetan terriers with these mutations provide a valuable model for a PARK9-linked disease and
possibly for manganese toxicity in synucleinopathies.
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Introduction
Neuronal ceroid lipofuscinosis (NCL) is a progressive neurodegen-
erative diseases characterized by brain and retinal atrophy and the
intracellular accumulation of autofluorescent lysosomal storage bodies
resembling lipofuscin in neurons and other cells. NCL has been
reported in several domestic animal species including cattle, goat,
sheep, cat and dog [1]. To this date eight forms of NCL have been
classified by clinical criteria, age of onset and presence of lysosomal
storage material in humans. Causative mutations in nine genes (PPT1,
TPP1, CLN3, CLN5, CLN6, CLN7, CLN8, CTSD and CLCN6)
have been identified [2–7]. All these mutations lead to an early-onset
NCL in human, sheep or dogs. Tibetan terriers show a late-onset
lethal form of NCL manifesting at 5–7 years [8]. The disease starts
most frequently with blindness in twilight and disorientation. Affected
dogs often appear nervous or anxious and the lack of motor
coordination becomes more severe with disease progression. Affected
dogs often have problems to jump up from the ground floor, or have
problems by going upstairs. At the final stages of the disease mild to
severe seizures have been observed. There are no treatment options
for affected dogs. Due to the late-onset of NCL in Tibetan terriers
some of the NCL susceptible dogs are bred and have progeny.
Tibetan terriers provide a valuable model for late-onset NCL as
no causative mutation for late onset NCL is known in human and
other species. NCL-genes known from human, sheep or other dog
breeds were evaluated and excluded for late-onset NCL in Tibetan
terriers in previous studies [9–13]. Parallel with our analysis, an
ATP13A2 frameshift mutation was identified as responsible for
adult-onset neuronal ceroid lipofuscinosis in Tibetan terriers [14].
Here, we describe the same association of the canine chromosome
(CFA) 2 region which harbors a splice-variant mutation in canine
ATP13A2 with late-onset NCL and analyse the mRNA of
ATP13A2 from NCL-affected Tibetan terriers to characterize the
possible effect of this mutation on the resulting protein.
Results
Sample collection
We collected samples from 24 NCL-affected Tibetan terriers
and 1,347 Tibetan terriers showing no clinical signs of NCL. Due
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years can manifest signs of NCL later in life. All 24 NCL-affected
Tibetan terriers showed clinical signs of NCL at an average of six
years. Necropsy was performed on seven of the NCL-affected
Tibetan terriers. Histological examination of retina, cerebellum,
cerebrum and spinal cord revealed gold-brown intracytoplasmic
pigment within retinal ganglion cells and neurons, respectively,
associated with degeneration and glioses using hematoxylin eosin
staining. In addition, cytoplasmic accumulations show a positive
signal using periodic acidic-Schiff reaction (PAS) and luxol fast
blue staining (LBF) (Figure 1). Brain iron accumulation using
Turnbull blue staining could not be found in affected dogs. The
phenotype of controls has been assured through reports of the
owners and veterinary examinations. All controls had an age of at
least 10 years and all their registered offspring was ascertained as
NCL-clear. The controls were distantly related to families with
NCL-affected dogs using five generation pedigree records. These
requirements made it difficult to collect a larger number of
controls fulfilling these requirements.
Mapping the causative genomic region
A genome-wide association analysis was performed for 12
Tibetan-terrier-NCL-cases and 7 Tibetan-terrier-NCL-controls
using the 127K canine Affymetrix SNP chip (Affymetrix, Santa
Clara, CA, USA). Controls were either not closely related with the
controls nor with the cases what caused an unbalanced design.
Chromosomal regions with genome-wide significant associations
(2log10p-values.3.2–3.5) were located on dog chromosomes
(CFA) 2 at 81.3–86.2 Mb, on CFA8 at 61 Mb, on CFA12 at
60.2–61.4 Mb, on CFA18 at 48.4–50.3 Mb, on CFA22 at 48 Mb
and on CFA37 at 29 Mb using PLINK for association testing
with adaptive permutations. We were not able to identify one
homozygous haplotype shared among all cases in these associated
regions. In order to rule out false positively associated regions and
to exclude heterogeneity, we used two different approaches. First,
we employed multipoint non-parametric linkage analyses and
secondly, we enlarged the number of cases and controls and we
tested SNPs from significantly associated regions on CFA2, 8, 12
and 18 in this larger data set. A total of 28 microsatellites (Table
S1) covering the associated and their adjacent chromosomal
regions were employed in three families including 107 Tibetan
terriers (Table S2, Figure S1). Mendelian inheritance and
correctness of marker transmission in the pedigrees genotyped
was confirmed using Pedstats [15]. A non-parametric multipoint
linkage analysis has been employed as this approach does not
require assumptions on the mode of inheritance and specification
of genetic parameters such as mode of inheritance, penetrance and
allele frequencies and so this approach should be useful for traits
when the correct mode of inheritance is unknown or assumptions
of genetic parameters may lead to ambiguous results or
heterogeneity might be of importance. We ruled out linkage for
NCL for the chromosomes 8, 18, 22 and 37 (Table S3). Evidence
for chromosome-wide significant linkage of the genomic region at
83.22–88.0 Mb on canine chromosome 2 was affirmed. A total of
13 SNPs (Table S4) was genotyped for the significantly associated
regions on CFA2, 8, 12 and 18 in 376 Tibetan terriers whereof 24
Figure 1. Luxol fast blue (LFB) staining. Of the (A) cerebrum and (B) retina from a NCL-affected Tibetan terrier. Intracytoplasmic LFB positive
pigment is indicated with arrows, bar indicates magnification for the micrograph (50 mm).
doi:10.1371/journal.pgen.1002304.g001
Author Summary
The neuronal ceroid lipofuscinosis (NCL) is a neurodegen-
erative storage diseases characterized by psychomotor
retardation, blindness, and premature death. NCL has been
reported in several dog breeds. NCL is characterized by
progressive brain and retinal atrophy and the intracellular
accumulation of autofluorescent lysosomal storage bodies
resembling lipofuscin. Tibetan terriers show a late-onset
and lethal NCL (age of onset 5–7 years) with an autosomal
recessive inheritance. The most frequently described first
symptom is blindness in twilight. In the disease progress
the affected dogs often appear nervous or anxious and the
lack of motor coordination becomes more severe. In the
final stages of this disease, mild but also severe seizures
have been observed by the owner. There are no treatment
options for affected dogs. Through a genome-wide
association analysis using the 127K canine Affymetrix
SNP chip, we found a 1 Mb candidate genomic region and
identified ATP13A2 as the most likely candidate for NCL. A
1-base pair deletion mutation within exon 16 of the
ATP13A2 gene caused the loss of an exonic splicing
enhancer and, consequently, the alternative splicing lead
to skipping of exon 16. This study provides a suitable
animal model for PARK9 in man to develop therapeutic
approaches.
ATP13A2 Mutation Causing Late-Onset NCL
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dogs. These 376 Tibetan terriers also contained the 107 dogs out
of the three families for linkage analysis and further 114 Tibetan
terriers to increase the number of family members of these three
families and in addition, 111 Tibetan terriers belonging to 17
different pedigrees. Genotyping was performed using the Seque-
nom technology (Sequenom, Hamburg, Germany). A significant
association (2log10p-value=6.7) could only be shown for one SNP
(BICF2S23719003) located on CFA2 at 83.94 Mb.
Mixed model analysis (MMA) was employed to ensure the
associated region on CFA2 and to narrow down the associated
region. The advantage of MMA over a simplistic approach
without considering any other effects in modelling association can
be seen in removing disturbing effects caused by data structure,
different levels of relationships among animals and inbreeding.
The model included the respective SNP genotypes, sex and
inbreeding coefficients as fixed effects and the genomic relation-
ship matrix for the random genetic effect of the animal. Using
MMA the NCL-region mapped to 83.71–84.719 Mb on dog
chromosome 2 (2log10p-value.200; Figure S2).
Identification and sequence analysis of candidate genes
In the region at 81.17–87.29 Mb on CFA2, we evaluated 14
genes for late-onset NCL in Tibetan terriers (Table S5). For
sequence analysis cDNA (Table S6) from two NCL-affected
Tibetan terriers and one control dog was used. Polymorphisms
detected (Table S7) were confirmed by re-sequencing genomic
DNA from four NCL-affected and four NCL-unaffected Tibetan
terriers. In the 39UTR of the canine MAPK PM20/PM21 gene one
SNP (XM_846908:c.766T.C) was detected showing co-segrega-
tion with the NCL-phenotype in Tibetan terriers. To evaluate this
mutation the same 376 Tibetan terriers employed for association
analysis were genotyped for the c.766T.C SNP (Table S8). In this
sample the NCL-associated allele C had a frequency of 0.265 and
the frequency of T/T genotypes was 0.559. The associations for
genotypes and alleles were significant at 2log10p.15 with x
2-
values of 194.58 and 94.16. Out of the 24 known NCL-affected
dogs, 22 affected could be correctly affirmed and from the 30
NCL-carriers ascertained from the pedigrees, 27 could be
correctly identified with the c.766T.C SNP.
Mutation analysis of ATP13A2
A candidate gene in close vicinity to the highest peaks of the
association analyses is the canine ATPase type 13A2 (ATP13A2)
encoding a lysosomal type 5 ATPase in human known to be
involved in Kufor-Rakeb-syndrome, a variant of Parkinson disease.
This gene is annotated at 84.09–84.11 Mb in Ensemble canine
genome reference sequence but not in CanFam 2.1 of NCBI. Using
the mRNA (Accession number NM_001141973) of ATP13A2 and
BLAST for canine expressed sequence tags (ESTs), we found five
canine ESTs for the ATP13A2 gene (Accession numbers
DN355771, DN374414, DN442497, DN743972, DN905373) and
could predict the canine ATP13A2 gene at 84.09–84.11 Mb on
CFA2. The canine ATP13A2 gene model contains like the human
transcript variant ENST00000326735 gene 29 exons with an open
reading frame of 3,522 bp coding for a protein with 1,173 amino
acids. The Ensemble canine cDNA reference sequence starts with
exon 2andexon1 ismissing.Re-sequencingofthecanineATP13A2
using cDNA from five NCL-affected and two NCL-unaffected
Tibetan terrier confirmed the predicted gene model. Mutation
analysis of the amplified sequences revealed exon skipping of exon
16 in all 5 NCL-affected dogs. To verify this mutation exon 16 and
its flanking introns were sequenced using genomic DNA from seven
NCL-affectedand30NCL-unaffected Tibetanterrier.Inthecanine
ATP13A2 gene a single base pair deletion within exon 16
(c.1620delG, Figure S3) was identified that causes skipping of exon
16 (Figure S4, Figure 2) in NCL-affected dogs. Sequencing of the
wholeintrons15and 16revealed nomutationsand thus,anintronic
mutation responsible for skipping exon 16 was not found. Exon
skipping does not shift the open reading frame (ORF) but leads to a
protein shortened by 69 amino acids (Figure S5). The loss of amino
acids in the canine ATP13A2 protein destroys the signatures of the
P-type cation transporting ATPase superfamily and sodium/
potassium-transporting ATPase, the E1-E2 ATPases phosphoryla-
tion site and a part of the domain of the haloacid dehalogenase-like
hydrolase (Figure S5).
Confirmation of the association in the Tibetan terrier
population
The single base pair deletion in exon 16 alters the restriction site
of the restriction enzyme BglI. Restriction fragment length
polymorphism (RFLP) was developed for screening the Tibetan
terrier population. In dogs with the genotype homozygous for G,
the 635 base pair (bp) PCR product was cut into two fragments
with 322 and 313 bp. In NCL-cases carrying the deletion
homozygously, the amplicons were not cut and only the 635 bp
product could be observed.
We screened 168 Tibetan terriers for the c.1620delG using BglI.
All genotyped 24 known NCL-cases were homozygous for the
deletion in exon 16 and the 35 known NCL-carriers heterozygous
for the deletion (Figure 3, Table 1). Screening of the 168 Tibetan
terriers revealed ten not yet known NCL-cases and further 35
NCL-carriers. The rest of the Tibetan terriers screened for
c.1620delG showed the wild type genotype. Tibetan terriers
expected as free for the c.1620delG mutation were homozygous
G/G like the dog reference sequence. The frequency of the
mutated allele was 0.309. To assure the observed results, 144 dogs
from eleven different dog breeds were genotyped for the
c.1620delG mutation. All 144 dogs did show the wild type
genotype (Table S10).
Discussion
A 1-bp deletion within exon 16 of ATP13A2 (c.1620delG) was
identified as responsible for NCL in the Tibetan terrier. All NCL-
cases reported in Tibetan terriers were homozygous for this
mutation and therefore heterogeneity seems unlikely for this
disease in Tibetan terriers. This c.1620delG mutation causes an
alternative splicing of exon 16 but not a frameshift mutation with a
premature termination codon as previously supposed [14]. As a
result of the in-frame loss of exon 16, the ATP13A2 protein is
shortened by 69 amino acids. Therefore, all NCL-affected Tibetan
terriers in the present study can synthesize this shortened
ATP13A2 protein. In humans, all three isoforms do not lack
exon 16. This new insight on the structure of the mutated protein
may explain why Tibetan terriers express only mild neurodegen-
erative symptoms and the onset of the disease is late in life.
Exonic substitutions often create or eliminate short elements
that inhibit or activate exon inclusion or splice-site selection [16–
18]. These splicing silencers or enhancers are present both in
exons (ESSs, ESEs) and introns (ISSs, ISEs) and have been derived
by computational and/or experimental approaches [19–20].
Searching the mutated canine ATP13A2 sequences using Human
Splicing Finder, version 2.4 (http://www.umd.be/HSF/) [19] we
could affirm that the 206 bp-exon 16 is no longer recognized by
splicing sites because the 1-bp deletion is responsible for a broken
exonic splicing enhancer motif sequence. However, the donor site
at the exon 15 boundary and the acceptor site at the exon 17
ATP13A2 Mutation Causing Late-Onset NCL
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process for exon 16 fails since the c.1620delG mutation destroys
the ESE motif (‘‘CCGCCTG’’ at cDNA positions 1614–1620)
within exon 16.
The ATP13A2 gene encodes a member of the P5 subfamily of
ATPases which transports inorganic cations as well as other
substrates. Mutations in this gene have been identified in Kufor-
Rakeb syndrome (KRS) patients, a familial form of Parkinson
disease (PARK9). One of the mutation studies described a 22 bp-
duplication mutation in exon 16 of the human ATP13A2 gene
[21]. A milder form of KRS than that reported for frameshift or
truncating mutations was caused by a G504R missense mutation
in exon 15 of the ATP13A2 gene, affecting the cytosolic loop close
to the predicted catalytic phosphorylation site [22]. The clinical
signs of PARK9 of this patient including aggressive behaviors
resemble some of the signs of NCL seen in affected Tibetan
terriers. Therefore, NCL in Tibetan terriers might be a mild form
of KRS with Parkinson’s disease-like symptoms since a truncating
mutation was not present in Tibetan terriers. The protein-
shortening mutation found in Tibetan terriers seems to be the
reason why only a partial overlap of disease symptoms among
KRS patients due to a truncating mutation and NCL-affected
Tibetan terriers is observed. A wide intra-familial clinical
variability of PARK9-linked disease seems to exist in humans.
In agreement with the NCL-affected Tibetan terriers, there were
also cases in man with no evidence for brain iron accumulation
[23]. Knock-down of the PARK9 orthologue in C. elegans enhances
a-synuclein (a–syn) misfolding [24]. This PARK9 functional
relationship with the a–syn pathobiology could be confirmed in
rat primary midbrain neuron cultures. On the other hand, yeast
PARK9 helps to protect cells from manganese toxicity [24].
To assure that the detected deletion within exon 16 is causative
for NCL in Tibetan terriers, all NCL-affected and NCL-carrier
dogs were genotyped and in addition, random samples of 144 dogs
from eleven different dog breeds were tested for the presence of the
c.1620delG mutation. All individuals of these nine different dog
breeds were homozygous for the wild type sequence. The
c.1620delG mutation of the ATP13A2 gene was not yet reported
as responsible for exon skipping and can therefore be regarded as
novel in this regard.
In conclusion, we identified the causal mutation for canine late-
onset NCL in the Tibetan terrier. This mutation (c.1620delG) is
located within exon 16 of ATP13A2 and leads to a shortened
protein through an alternative splicing process for exon 16 due to a
broken ESE motif. The pathobiology may be mediated through
the connection of ATP13A2 to the a–syn network. Tibetan terriers
carrying the susceptible genotype for NCL may be a valuable
model for unraveling the pathobiology of a PARK9-linked disease
and testing the role of manganese toxicity in synucleinopathies.
Knowledge of the causative mutation for late-onset NCL in
Tibetan terriers allows genetic testing of these dogs to avoid
matings of carrier animals. So the breeders are able to eliminate
this disease in their breeding lines.
Materials and Methods
Ethics statement
All animal work has been conducted according to the national
and international guidelines for animal welfare. All blood-
sampling of NCL-affected dogs was done in veterinary clinics for
small animals during the routine of diagnosis of NCL. The blood
samples of unaffected dogs were provided from veterinarians in
Figure 2. Mutation analysis of exon 16 using cDNA. Primer pairs used were ATP13A2_F7 and ATP13A2_R7. Agarose gel analyses revealed exon
16 skipping for NCL-affected Tibetan terriers.
doi:10.1371/journal.pgen.1002304.g002
Figure 3. Detection of the ATP13A2 one base pair deletion. The deletion was genotyped using a restriction fragment length polymorphism on
a 4% agarosegel and the restriction enzyme BglI. NCL-affected Tibetan terriers show only one fragment, NCL-carriers show two fragments and NCL-
unaffected Tibetan terriers show only one fragment, because the 312 and 323 bp fragments are not separated on the agarosegel.
doi:10.1371/journal.pgen.1002304.g003
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veterinary clinics for small animals after euthanasia.
Sample collection and processing
EDTA-blood samples from affected and control dogs were
collected from 1,371 Tibetan terriers. Thereof 24 Tibetan terriers
were NCL-affected, 35 were NCL-carriers because they were
parents or offspring of NCL-affected dogs and the other 1,312
Tibetan terriers had a clear or unknown phenotype. Except of one
NCL-affected Tibetan terrier from Switzerland all NCL-affected
Tibetan terriers were from Germany. Within the known NCL-
carriers, three dogs were from Denmark, two from Switzerland
and each one from Finland and USA.
DNA extraction
Genomic DNA was extracted from EDTA blood samples
through a standard ethanol fractionation with concentrated
sodiumchloride (6 M NaCl) and sodium dodecyl sulphate (10%
SDS). Concentration of extracted DNA was determined using the
Nanodrop ND-1000 (Peqlab Biotechnology, Erlangen, Germany).
DNA concentration of samples for SNP chip analysis was adjusted
to 50–70 ng/ml.
RNA extraction and cDNA synthesis
For cDNA analysis, biopsies from conjunctiva and cerebrum of
five NCL-affected dogs during the pathological examination were
taken. These samples were taken 15–30 minutes after the dogs
were euthanised.
Tissue samples were conserved using RNA-later solution
(Qiagen, Hilden, Germany). The RNA was extracted from the
cerebrum tissues using the RNeasy Lipid Tissue Mini Kit (Qiagen)
and transcribed into cDNA using SuperScript III Reverse
Transcriptase (Invitrogen, Karlsruhe, Germany).
Statistical analysis
Genome-wide association analyses were performed using the
127K canine Affymetrix SNP chip (Affymetrix, Santa Clara, CA,
USA). DNA from 12 Tibetan-terrier-NCL-cases and 7 Tibetan-
terrier-NCL-controls were used for a genome-wide association
analysis. The phenotype of controls has been assured through
reports of the owners and veterinary examinations. All controls
had an age of at least 10 years and all their registered offspring was
ascertained as NCL clear. The controls were preferably unrelated
to families with NCL affected dogs using five generation pedigree
records.
Quality criteria were minor allele frequencies (MAF) .2% and
SNP genotyping rates .95% for the genome-wide association for
NCL of the resulting 111,525 SNPs from the canine 125K SNP
chip were performed using PLINK, version 1.07 (http://pngu.
mgh.harvard.edu/purcell/plink/) [25] and Tassel, version 2.1
[26]. Genome-wide significance was ascertained through adaptive
permutation testing using a maximum of 5,000,000 permutations.
Non-parametric multipoint linkage (NPL) analysis was per-
formed for the NCL-affected Tibetan terriers and their relatives
from three different families using MERLIN 1.1.2 [27]. Linkage
among NCL and microsatellites was estimated using the
proportion of alleles identical by descent (IBD) for affected
animals. The NPL statistics Zmean and the LOD (logarithm of the
odds) scores were employed for detection of allele sharing among
affected family members. The maximum (minimum) achievable
Zmean and LOD score were 6.83 (22.10) and 2.60 (20.31)
indicating enough power to detect chromosome-wide significant
linkage. In the case of no linkage, Zmean approaches the
minimum achievable value due to an equal distribution of alleles
among affected relatives. When linkage is present under the
alternative hypothesis, the proportion of alleles IBD significantly
deviates from the expected IBD proportions of the null hypothesis.
We employed multipoint analyses in order to use marker
information from the whole chromosome through linked infor-
mative markers and to increase power of linkage analysis.
Sequencing and genotyping
For cDNA analysis of genes in the associated genomic region
annotated canine mRNA sequences were used. To assure the
annotation we searched the dog expressed sequence tag (EST)
archive (http://www.ncbi.nlm.nih.gov/genome/seq/CfaBlast.html)
for ESTs by cross-species BLAST searches with the corresponding
human reference mRNA sequences.
For PCR primer design the PRIMER3 software (http://frodo.
wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) were used. Prim-
er pairs used for cDNA amplification of the 14 positional
candidate genes are given in Tables S6 and S9. The PCR
reactions were performed in a total volume of 50 ml containing
10 ng of genomic DNA as template, 10 pmol of each primer and
1 U Taq polymerase (MP Biomedicals, Eschwege, Germany).
Thermocycling was carried out under the following conditions:
initial denaturation at 94uC for 4 min was followed by 35 cycles of
94uC for 30 s, 58–61uC for 30 s, 72uC for 1:20 min and a final
step with 72uC for 5 min before cooling at 4uC for 10 min. Primer
pairs for amplification the genomic DNA of canine ATP13A2 exon
16 were as follows: ATP13A2_F 59-GACCTGCCGTAGGGT-
GAAG-39 and ATP13A2_R59-AAGCTTCCTTCCTGGGC-
TAC-39. Amplicons were directly sequenced using an ABI 3700
capillary sequencer (Life Technologies, Darmstadt, Germany).
Afterwards sequence data were analyzed using Sequencher
software version 4.7 (GeneCodes, Ann Arbor, MI, USA).
Microsatellite development and analysis
We genotyped 28 microsatellites on CFA2, 8, 18, 22 and 37. We
used 16 markers of the canine minimal screening set 2 [28] and 12
newly developed markers. Microsatellite motifs were identified in
the assembled dog sequences (dog genome assembly 2.1) using
BLAST http://www.ncbi.nlm.nuh.gov/entrez/query.fcgi). The
criterion for markers to be included in this set was more than 15















G / G- -- -1 8 1 0 9
G/delG - - 35 97 - -
delG/delG 24 21 - - - -
doi:10.1371/journal.pgen.1002304.t001
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Prior to primer design using PRIMER3 repetitive sequences were
masked employing repeatmasker (http://www.repeatmasker.org).
The average marker distance was about 0.5 Mb at 81.5–88.0 Mb
on CFA2.
The PCR was carried out with an initial denaturing for 4 min at
94uC followed by 38 cycles with denaturing at 94uC for 30 sec,
optimum primer annealing temperature (Table S1) for 30 sec and
elongation at 72uC for 45 sec. All PCR reactions were performed
in 12.0-ml reactions using 10 pmol of each primer, 0.2 ml dNTPs
(100 mM) and 0.1 ml Taq-DNA-Polymerase (5 U/ml) (Q-Biogen,
Heidelberg, Germany) in the reaction buffer supplied by the
manufacturer for 2 ml template DNA. The forward primers were
labelled fluorescently with IRD700 or IRD800. For the analysis of
the marker genotypes, PCR products were size-fractionated by gel
electrophoresis on an automated sequencer (LI-COR, Lincoln,
NE, USA) using 4% polyacrylamide denaturing gels (Rotiphorese
Gel40, Carl Roth, Karlsruhe). Allele sizes were determined using
an IRD700- and IRD800-labelled DNA ladder. Genotypes were
assigned by visual examination.
Pathological-histological examination
Formalin-fixed, paraffin-embedded tissue samples of the retina,
cerebellum, cerebrum and spinal cord were examined by
histology. Briefly, 3 mm-thick sections were cut on a microtome
and mounted on glass slides. Subsequently slides were stained with
hemotoxylin and eosin (HE), periodic acid-Schiff reaction (PAS),
Turnbull blue and luxol fast blue staining (LFB).
Supporting Information
Figure S1 Pedigree structure of the three Tibetan terrier families
used for linkage analysis. (A) Family 1, (B) family 2 and (C) family
3. Tibetan terriers in the families marked with a ‘‘g’’ were
genotyped for linkage analysis and Tibetan terriers marked with
‘‘chip’’ were also used for the 127K canine Affymetrix SNP chip
analysis. Some females were mated to different sires causing
mating loops.
(DOC)
Figure S2 Manhattan-plot of the 2log10 P-values for the
genome-wide association analysis of late-onset neuronal ceroid
lipofuscinosis (NCL) in Tibetan terriers from a mixed model
analysis using TASSEL, version 1.07. The highest 2log10 p-values
(.200) were obtained for dog chromosome 2 at 83.7–84.7 Mb.
(DOC)
Figure S3 Causative mutation for late-onset NCL in Tibetan
terriers. Chromatograms of genomic sequences of ATP13A2 exon
16 from each one NCL-affected, NCL-carrier, NCL-free Tibetan
terrier and the dog reference sequence. The 1-bp deletion at base
pair 96 of exon 16 marked by a red rectangle and 15 bp up- and
15 bp downstream sequence are shown in the lower part of the
figure.
(DOC)
Figure S4 Exon splicing patterns of transcripts from normal and
mutant ATP13A2 alleles. cDNA from the normal allele contains
exon 16, the mutant allele skips exon 16 and exon 15 is spliced to
exon 17 splice acceptor site. Skipping of exon 16 leads to a loss of
69 amino acids. The open reading frame remained unchanged
through the loss of exon 16.
(DOC)
Figure S5 CLUSTAL 2.0.12 multiple protein alignment. The
human ATP13A2 isoform 1 protein has 1175 amino acids, the
normal canine ATP13A2 protein 1173 amino acids and the canine
NCL-associated ATP13A2 protein is shortened by 69 amino acids.
(DOC)
Table S1 Microsatellite markers for fine mapping the genomic
region on canine chromosome 2, 8, 18, 22 and 37. The primer
pairs used are given with their position in mega bases (Mb),
annealing temperature (AT), heterozygosity (HET) and their
polymorphism information content (PIC). HET and PIC were
calculated for 107 Tibetan terriers.
(DOC)
Table S2 Tibetan terrier families used for linkage analysis. For
linkage analysis 20 NCL-affected and 87 NCL-unaffected Tibetan
terriers were genotyped in three families enclosing a total of 107
Tibetan terriers.
(DOC)
Table S3 Chromosome-wide error probabilities (pZmean,p LOD)
for multipoint non-parametric linkage analysis in 107 Tibetan
terriers for the NCL-phenotype using 28 microsatellites.
(DOC)
Table S4 Summary results for the SNPs used for association
analysis. SNP accession numbers, positions and alleles genotyped
for 376 Tibetan terriers with their minor allele frequencies (MAF)
and P-values for genotypic association with NCL.
(DOC)
Table S5 Candidate genes evaluated for late-onset NCL in
Tibetan terriers. Gene name, annotation by NCBI or Ensembl,
position in mega bases (Mb) and involvement in disease/function
of genes in human.
(DOC)
Table S6 Primer pairs for cDNA amplification and the genomic
regions of the 14 canine candidate genes. The primer pairs are
given with their sequences, annealing temperature (AT), product
size in base pairs (bp) and the target position.
(DOC)
Table S7 Single nucleotide polymorphisms detected in coding
and untranslated sequences of the evaluated genes for NCL in
Tibetan terriers. SNP nomenclature, position and possible amino
acid exchange are given.
(DOC)
Table S8 Genotyping 376 Tibetan terriers for the canine MAPK
PM20/PM21 c.766T.C SNP.
(DOC)
Table S9 Primer pairs for cDNA amplification of the
canine ATP13A2 gene and its genomic DNA surrounding exon
16. The primer pairs are given with their sequences, annealing
temperature (AT), product size in base pairs (bp) and the target
position.
(DOC)
Table S10 Dog breeds other than Tibetan terrier genotyped for
the ATP13A2 c.1620delG mutation.
(DOC)
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